| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-018 | | --- | --- | --- | --- | | 债券代码：113585 | 债券简称：寿仙转债 | | | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 浙江寿仙谷医药股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2023 年 04 月 19 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日下午 15:00-16:30 参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 二、说明会召开的时间、地点及活动日程 （一）会议召开时间：2023 年 05 月 1 ...

2022 年第三季度报告 单位：元 币种：人民币 1 / 13 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|----------------------------------------|----------------|------ ...

Financial Performance - The company reported a half-year performance summary with no significant risks impacting operations[6]. - The company achieved a net profit attributable to shareholders of RMB 82.02 million, a year-on-year increase of 49.13%[22]. - The basic earnings per share increased to RMB 0.42, representing a growth of 44.83% compared to the same period last year[22]. - Operating revenue for the first half of the year was RMB 349.53 million, up 10.09% from RMB 317.49 million in the previous year[23]. - The net cash flow from operating activities reached RMB 184.90 million, reflecting a growth of 30.07% year-on-year[23]. - The company’s total assets increased by 4.31% to RMB 2.05 billion compared to the end of the previous year[23]. - The weighted average return on net assets rose to 4.96%, an increase of 1.00 percentage points from the previous year[22]. - The company reported a total revenue of 29,763.49 million RMB for the first half of 2022, with a gross margin of 86.31%[91]. - The company achieved an operating profit of ¥82,873,711.88, up from ¥56,397,609.83, reflecting a growth of 46.8% year-over-year[170]. - The company reported a total comprehensive income of ¥86,813,197.44 for the first half of 2022, compared to ¥58,252,348.06 in the same period of 2021, indicating a growth of 48.9%[171]. Corporate Governance - The board of directors confirmed the authenticity and completeness of the financial report[4]. - The report is unaudited, ensuring transparency in financial disclosures[4]. - The company has established an information management system to optimize market operations, resulting in improved profit margins[69]. - The company has committed to transparency and adherence to corporate governance standards in its operations[126]. - The company has maintained compliance with legal regulations regarding related party transactions and has ensured fair trading practices[126]. Risk Management - The management has outlined potential risks in the "Management Discussion and Analysis" section[6]. - The company emphasizes the importance of investor awareness regarding investment risks[5]. - The company faces risks related to natural disasters affecting the supply of key raw materials like Lingzhi and Dendrobium, which could impact production[98]. - The company has a risk of production qualification being revoked or not renewed, which could adversely affect operations[100]. Market Strategy and Expansion - The company plans to continue expanding its product line, focusing on high-quality traditional Chinese medicine and health products[28]. - The company maintains a strategy of optimizing its industrial layout and enhancing its core competitive advantages in the market[28]. - The company aims to leverage its advantages in seed sources and full industry chain to expand sales channels and establish "Shouxiangu" as a nationally recognized brand[47]. - The company plans to expand its market presence, focusing on the development of new products and technologies in the health sector[88]. - The company has established a "full industry chain" development model for products like Lingzhi and Dendrobium, ensuring standardized cultivation from breeding to processing[51]. Research and Development - The company has developed and certified three new Dendrobium varieties: "Xianhu 1," "Xianhu 2," and "Xianhu 3," which are characterized by high survival rates and strong resistance[57]. - The company has developed a patented "four lows and one high" ultrasonic low-temperature airflow breaking technology, significantly improving product safety and efficacy[62]. - The company has initiated several clinical trials related to its Ganoderma lucidum spore powder, including studies on its effects on immune function and its application in cancer treatment[72]. - The company received three new invention patents during the reporting period, enhancing its research and development capabilities[70]. Social Responsibility - The company actively donated products to frontline medical personnel during the COVID-19 pandemic, including donations to various hospitals and organizations[122]. - The "Shouxiangu Caring for Tumor Students" public welfare initiative has entered its fifth season, highlighting the company's commitment to social responsibility[122]. - The company has been recognized for its contributions to technological innovation and rural revitalization efforts by various provincial departments[121]. Shareholder Information - The company distributed a cash dividend of RMB 4.05 per 10 shares, totaling RMB 60.32 million, and increased its total share capital to 197.20 million shares[23]. - The company plans to issue convertible bonds, with a feasibility analysis report presented for shareholder approval[111]. - The total share capital after the distribution is 197,195,916 shares, reflecting an increase due to the capital reserve conversion[138]. - The company has no significant litigation or arbitration matters during the reporting period[129]. Financial Health - The company has maintained a strong debt repayment capability, having repaid all bank loans on time and in full without any overdue debts[159]. - The company’s credit rating remains stable at "AA-" for both the company and the convertible bonds, with no significant changes in creditworthiness[158]. - The total liabilities increased to ¥399,947,341.65 from ¥342,410,273.94, a growth of about 16.8%[164]. - The total owner's equity at the end of the current period reached approximately 1,647,038.7 million, reflecting growth in capital reserves[184].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人及会计机构负责人（会计主管人员）祝彪保证季度报告 中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 \n变动幅度 ( ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人及会计机构负责人（会计主管人员）祝彪保证季度报告 中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | ...

Dividend and Capital Management - The company plans to distribute a cash dividend of 4.05 CNY per 10 shares (including tax) and to increase capital by converting 3 shares for every 10 shares held[6]. - The company has committed to maintaining the distribution ratio even if there are changes in total share capital before the dividend distribution date[6]. Risk Management and Audit - The company has confirmed that there are no significant risks affecting its production and operations during the reporting period[8]. - The company has received a standard unqualified audit report from the accounting firm[5]. - The board of directors and management have ensured the accuracy and completeness of the annual report[4]. - There are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[8]. - The company has not faced any substantial risks that could impact its operations during the reporting period[8]. Financial Performance - The company achieved operating revenue of CNY 767,137,327.36 in 2021, representing a year-on-year growth of 20.61%[27]. - The net profit attributable to shareholders reached CNY 200,826,526.21, an increase of 32.37% compared to the previous year[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 198,751,369.45, reflecting a growth of 45.19% year-on-year[27]. - The net cash flow from operating activities was CNY 296,699,128.48, up by 15.74% from the previous year[27]. - The company's total assets at the end of 2021 were CNY 1,962,459,613.29, a 15.47% increase from the end of 2020[27]. - The net assets attributable to shareholders increased to CNY 1,619,664,568.66, marking a growth of 22.12% year-on-year[27]. - Basic earnings per share for 2021 were CNY 1.34, up 25.23% from CNY 1.07 in 2020[27]. Research and Development - The company launched 11 new research projects in 2021, with 8 successfully approved, including 2 national-level projects[41]. - The company applied for 20 patents in 2021, with 6 patents granted, including 1 foreign invention patent[42]. - The company established three major databases: phenotype library, gene bank, and chemical substance metabolism library[42]. - The company’s management and R&D team has extensive experience in the industry, ensuring a strong competitive advantage in technology and marketing[86]. - The company has focused on several key R&D projects, with the highest investment in the clinical efficacy of broken wall ganoderma spore powder for late-stage cancer patients, totaling 748.14 million RMB, which is 0.98% of operating revenue[160]. Market Expansion and Sales Strategy - The company launched new sales channels, including the establishment of Zhejiang Shouxiangu Jishi Health Development Co., Ltd. to explore national market agency systems[30]. - The company aims to innovate cloud sales through platforms like Shouxiangu Mini Programs, enhancing its market strategy[30]. - The company is actively expanding its market presence and has signed agreements for land transfer in the Shigehu area, covering 8,000 acres[47]. - The company plans to expand its market presence outside Zhejiang by increasing promotional efforts and recruiting distributors for spore powder tablets[106]. - The company aims to enhance brand awareness and product visibility through increased marketing efforts, particularly in ground promotions and customer experiences[179]. - The company aims to establish a world-class research and innovation platform for rare plant medicines, utilizing AI, big data, and IoT technologies[193]. - The company is focusing on expanding its market presence through a diversified e-commerce strategy and establishing a nationwide distribution network[194]. Product Development and Quality Control - The company has successfully developed three new products: "Shouxiangu brand Dendrobium candidum tablets," "Shouxiangu brand Dendrobium candidum and Ganoderma lucidum granules," and "Shouxiangu brand Batocera rufipennis mycelium powder," which have completed the registration process for domestic health food[43]. - The company achieved a 100% quality pass rate for traditional Chinese medicine products, including proprietary Chinese medicines, Chinese medicine pieces, health foods, and agricultural products[46]. - The company has implemented a comprehensive quality control system throughout the production process, adhering to national and international standards[85]. - The company’s organic product production management has been certified with a 100% compliance rate, ensuring high-quality raw material production and supply[46]. Sales Performance - The company’s sales revenue showed steady growth, with several regions exceeding their annual sales targets[37]. - Revenue from online sales reached CNY 185.45 million, with a year-on-year growth of 27.33%[98]. - The company maintained a stable market presence in Zhejiang Province, with sales from this region accounting for 63.45% of total revenue in 2021[105]. - The overall sales revenue for the year reached 75,999.03 million RMB, a significant increase from 62,983.81 million RMB in the previous year[169]. Investment and Financial Management - The company reported a net cash outflow from investment activities of CNY 233.72 million, indicating significant investment in growth initiatives[91]. - The total investment cash flow was -233.72 million RMB, primarily due to investments in convertible bond projects[126]. - The company has made significant equity investments, including a 28.55% stake in Yecun Investment, with a year-end balance of 2,760,000.00 RMB[185]. Marketing and Advertising - Advertising expenses increased to 19,853.92 million RMB in 2021, making up 62.09% of total sales expenses, up from 46.73% in 2019[179]. - The proportion of advertising expenses to total sales expenses has shown a consistent increase, indicating a strategic focus on marketing[179]. - The company aims to expand its internet sales channels further, leveraging platforms like Tmall and JD.com to enhance market reach[172].

2021 年第三季度报告 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|-------|--------------------------------------|------------------------ ...

2021 年半年度报告 公司代码：603896 公司简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 ZhejiangShouxianguPharmaceuticalCo.,Ltd. （浙江省武义县壶山街道商城路 10 号） 2021 年半年度报告 二〇二一年八月二十五日 1 / 164 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李明焱、主管会计工作负责人傅华平及会计机构负责人（会计主管人员）傅华平 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的前瞻性描述不构成公司对投资者的实质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保 ...

2020 年年度报告 | --- | --- | --- | --- | |------------|--------|-------|--------------------| | | | | | | 公司代码： | 603896 | | 公司简称：寿仙谷 | | 债券代码： | 113585 | | 债券简称：寿仙转债 | | 转股代码： | | | 债券简称：寿仙转股 | 191585 浙江寿仙谷医药股份有限公司 ZhejiangShouxianguPharmaceuticalCo.,Ltd. （浙江省武义县壶山街道商城路 10 号） 2020 年年度报告 二〇二一年四月二十八日 1 / 265 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人李明焱、主管会计工作负责人傅华平及会计机构负责人（会计主管人 员）傅华平声明：保证年度报告 ...

2021 年第一季度报告 | --- | --- | --- | --- | |------------|--------|-------|--------------------| | | | | | | | | | | | 公司代码： | 603896 | | 公司简称：寿仙谷 | | 债券代码： | 113585 | | 债券简称：寿仙转债 | | 转股代码： | 191585 | | 债券简称：寿仙转股 | 浙江寿仙谷医药股份有限公司 ZhejiangShouxianguPharmaceuticalCo.,Ltd. （浙江省武义县壶山街道商城路 10 号） 2021 年第一季度报告 二〇二一年四月二十八日 1/22 2021 年第一季度报告 重要提示 . 一、 二、 公司基本情况 . 11Í 重要事项 . 四、 附录 . 目录 2/22 2021 年第一季度报告 单位：元币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 ...